LLYEli Lilly & Co. — stock analysis & sentiment
Eli Lilly & Co. (LLY) last closed at $1,240.34, near the top of its 52-week range of $793.82–$1,292.65. Composite market sentiment across 2 analyses is positive (+29 on a −100 to +100 scale), as of Oct 20, 2026.
Produced by the Synoptiv Research Engine from public financial data. Read the methodology.
Go beyond the overview
The thesis, technical signals, risk levels, and complete evidence — everything the overview leaves out.
What changed
Since the previous analysis (v1) on Aug 22, 2026.
LLY fell to $1,240.34, from $1,255.40 at the previous analysis.
Composite sentiment held steady at +29 (positive).
42 headlines since the last analysis — 25 positive, 2 negative, 15 neutral.
Market cap fell -1.20%, from $1.12T to $1.11T.
The written analysis on this page was refreshed for v2.
What the data says
An overview of the public data behind LLY.
Eli Lilly last closed at $1,240.34, about 4% below its 52-week high of $1,292.65 and roughly 56% above its 52-week low of $793.82. From low to high, the range spans more than 60%. That is a wide band for a company of this size, and the stock now sits near the top of it.
At a market capitalization of about $1.1 trillion, the shares trade at roughly 42 times trailing earnings and 26 times forward earnings. The gap between those two figures reflects the market's expectation that earnings will rise substantially from here. Revenue grew about 48% and the profit margin is near 34%, so the business converts a large share of its sales into profit. Price-to-book stands near 33, which means the market values the company far above the accounting value of its assets. The dividend yield is a modest 0.55%. A beta of about 0.45 means the stock has historically moved less than half as much as the broader market.
Recent news has mixed Lilly-specific coverage with wider sector stories. The company-focused items include a note that the stock dipped on a day the market rose, commentary pieces on the shares, and previews of how sales from its GLP-1 drugs may shape upcoming third-quarter results. The rest centers on the industry: competition in the weight-loss market, including Viking Therapeutics' $575 million capital raise, Pfizer's third-quarter outlook, and a research report on growth in the migraine treatment market.
Written from public market data. Research, not financial advice — the thesis, signals and risk levels are in the full report.
Price chart
LLY daily price history.
Market sentiment
A composite of the public market data in this analysis, from −100 (bearish) to +100 (bullish).
This gauge blends news tone, analyst views, insider and congressional activity, and price momentum into a single score. The full report breaks down each driver and pairs it with the thesis.
See the full sentiment breakdown in the report →Key stats
A public snapshot of commonly used market and valuation measures.
Valuation & size
- Market cap
- $1.11T
- Enterprise value
- $1.15T
- P/E (TTM)
- 41.64
- Forward P/E
- 26.27
- Price / book
- 32.64
- Price / sales
- 13.88
Profitability & growth
- Net margin
- 33.53%
- Revenue growth
- +47.70%
- Earnings growth
- +26.20%
- Dividend yield
- 0.55%
Price & risk
- Beta
- 0.45
- Average volume
- 2.46M
From noise to signal. The full report has LLY’s thesis, trade signal, and risk levels.
About Eli Lilly & Co.
Eli Lilly and Company is a pharmaceutical company that discovers, develops, manufactures, and markets medicines. It sells them in the United States, Europe, China, Japan, and other international markets. Its largest area is cardiometabolic health. This includes a long-standing line of insulins, such as Humalog, Humulin, and Basaglar, and type 2 diabetes treatments including Mounjaro, Trulicity, and Jardiance. It also sells Zepbound for obesity. Lilly also has an oncology portfolio. It includes Verzenio and Inluriyo for breast cancer, Retevmo for certain lung cancers, Jaypirca for chronic lymphocytic leukemia, and Cyramza and Erbitux for gastrointestinal and head and neck cancers. Its immunology products include Taltz, Olumiant, Omvoh, and Ebglyss. In neuroscience, it offers Emgality for migraine and cluster headache and Kisunla for early symptomatic Alzheimer's disease. The company works with several partners. It shares the Jardiance product family with Boehringer Ingelheim. It holds licensing agreements with Almirall for Ebglyss and with Chugai Pharmaceutical for the investigational oral drug orforglipron. It also has research collaborations with several biotechnology firms in areas such as genetic medicine and neurological disease. Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest news
Recent headlines related to LLY, with vendor tone.
LLY — frequently asked questions
Answered from the public data on this page.
What is the current market sentiment for LLY?
As of Oct 20, 2026, Eli Lilly & Co. (LLY) carries positive (+29 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.
How has LLY stock been performing?
Eli Lilly & Co. last closed at $1,240.34, near the top of its 52-week range of $793.82–$1,292.65.
What is LLY's market cap and valuation?
Eli Lilly & Co. has a market capitalization of about $1.11T, a trailing P/E of 41.6, a dividend yield of 0.55%.
What sector is LLY in, and who are its competitors?
Eli Lilly & Co. operates in the Healthcare sector, specifically Drug Manufacturers - General. Comparable companies include JNJ, MRK, PFE, BMY, RPRX.
Where can I find a full analysis of LLY?
The full LLY report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.
Analysis history
Every saved analysis, newest first.